Hologic published a retrospective study of 7,500 digital breast tomosynthesis exams performed between 2016 and 2019 at Massachusetts General Hospital. The study, appearing in the American Journal of Roentgenology, found that its Genius AI Detection solution flagged 32% of cases that had been read as negative and correctly localized 90% of known cancer cases.
The findings demonstrate that the AI system can identify invasive ductal carcinomas and lymph‑node‑positive cancers that radiologists missed, potentially raising early detection rates. The study also noted limitations, including its single‑center design, a predominantly Caucasian patient population, and the use of a specific AI software version (Genius AI Detection 2.0).
Hologic’s leadership highlighted the clinical value of the technology. Mark Horvath, President of Breast and Skeletal Health Solutions, said the study provides critical insights that will guide future product development and help expand adoption of AI‑enhanced mammography. The company expects that broader deployment of the platform could translate into increased market share and higher recurring service revenue.
The study comes as Hologic reports strong financial results for fiscal 2025. In the fourth quarter, the company generated $1,049.5 million in revenue and a non‑GAAP diluted EPS of $1.13. The company also confirmed a definitive acquisition agreement with Blackstone and TPG, announced in October 2025, which is expected to shape the company’s strategic trajectory.
Dr. Manisha Bahl, Associate Director of Quality for Breast Imaging at Mass General Brigham, noted that while additional research is needed, the data are promising and highlight AI’s potential to redefine breast cancer detection. Hologic’s AI study, combined with its ongoing acquisition, positions the company to capitalize on the growing demand for advanced imaging solutions and to strengthen its competitive stance in the women's health diagnostics market.
The AI study underscores Hologic’s commitment to innovation amid a competitive landscape that includes other medical technology firms investing in AI for mammography. By demonstrating measurable improvements in detection, Hologic reinforces its leadership position and may accelerate adoption of its AI platform across clinical settings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.